Aubrey, B., Miller, P., Graubert, T., Chen, Y., Guarecuco, R., Fathi, A., Hasserjian, R., Brunner, A. (2025). A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies. Blood. https://doi.org/10.1182/blood-2025-2086